

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, December 11, 2020

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	-	Heather Preuss, MD	X
Dana Darger, RPh, Chair	X	Matthew Stanley, DO	X
Mikal Holland, MD	X	Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Mike Jockheck, DSS Staff	X
Kelley Oehlke, PharmD	X	Matthew Ballard	X
Lenny Petrik, PharmD	X	Bill Snyder, DSS Staff	X

Administrative Business

Darger called the meeting to order at 1:05 pm. The minutes of the September meeting were presented. Ladwig made a motion to approve. Preuss seconded the motion. The motion was unanimously approved via roll call vote.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from July 1, 2020 to September 30, 2020. A total of 1,900 PAs were reviewed of which 178 requests (9.4%) were received via telephone and 1,051 requests (55.3%) were received via fax, and 671 (35.3%) were reviewed via electronically. This was a 40% increase of PAs received from the previous quarter.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from July 1, 2020 to September 30, 2020. The top five therapeutic classes based on paid amount were atypical antipsychotics, amphetamines, disease-modifying anti-rheumatic agents, anticonvulsants, and cystic fibrosis correctors. The top 15 therapeutic classes make up 24.52% of total claims. It was noted that under Enzymes, Strensiq made the top 15 therapeutic class based on amount paid for the first time. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 11.28% of total claims. New utilization for Hemlibra and Compounds were noted on the top 50 drugs based on amount paid.

Old Business

90-Day Fill

An update was provided on the 90-day fill which was implemented on 10/1/2020. A 90-day supply of generic maintenance medication is allowed after member establishes three monthly fills. Most of the utilization currently were for SSRI, PPI, HMG, anticonvulsants, ACEI, and thyroid medications. Provider notification will be sent February 2021 which will increase adoption of the 90-day fill.

Nayzilam & Valtoco utilization

Committee was satisfied with the utilization for Nayzilam and Voltoco. Committee decided not to monitor quarterly. Utilization will be monitored and brought back to the Committee if it is atypical.

Humira CF PA

Proposed PA criteria for Humira citrate-free (CF) were reviewed. Jenna Gianninoto from AbbVie provided public comment on Humira CF injectables. Preuss inquired whether cost difference warranted PA criteria for CF injectables. Jockheck confirmed substantial savings to the State. Pediatric dosage of Humira CF injections are the only ones available. Preuss requested children started on citrate-free to continue CF. Committee discussed electronic compared to manual PA reviews. Ladwig made a motion to add PA to Humira CF. Van Gilder seconded the motion. The motion was unanimously approved via roll call vote.

Atypical antipsychotic utilization in children

Committee reviewed atypical antipsychotic utilization in children 17 years old and under. Members currently taking 2 or more antipsychotics were specifically reviewed. Stanley referenced best practice on utilization of two or more atypical antipsychotics especially for general health maintenance with significant potential medical ramifications for children on high dose antipsychotics. Darger suggested referring these members to DUR and conduct an in-depth analysis of the 17 members taking 3 or more atypical antipsychotics. Jockheck brought forth adding PA for members needing a third atypical antipsychotic. Stanley made a motion for members taking 3 or more atypical antipsychotics to require PA. Ladwig to second the motion. The motion was unanimously approved via roll call vote. Committee requested to review PA criteria at the next meeting. Darger inquired if there was any public comment. There were none.

Review of Reyvow, Ubrelvy, Nurtec ODT fax form

Committee reviewed the Reyvow, Ubrelvy, and Nurtec ODT fax form. Mary Jenkins from AbbVie was available for any questions on Ubrelvy. Mary Martin from Biohaven was available to address any questions on Nurtec ODT. Holland made the motion to approve PA on Reyvow, Ubrelvy and Nurtec ODT. Stanley seconded the motion. The motion was unanimously approved via roll call vote.

Opioid update

The committee reviewed 3Q20 opioid outcomes compared to previous quarters from the opioid initiatives. There was a slight increase in opioid utilization and opioid utilizers during third quarter which corresponded with the general increase in Medicaid eligible members and utilizers.

New Business

Antidiabetics PA approval review

Committee reviewed the PA approval rate for antidiabetic drugs. Based on current trend, no changes were needed.

Ulcer drugs PA approval review

Committee reviewed the PA approval rate and utilization for proton pump inhibitors. Ladwig made the motion to remove PA on esomeprazole capsule, and Petrik seconded the motion. The motion was unanimously approved via roll call vote.

Van Gilder requested to review SNRI PA approvals at the next meeting.

Accumulation edit

Jockheck discussed the accumulation edit is in preliminary stages for consideration. Pruess commented that this edit could impact the IHS community since they may have transportation issues certain days off the reservation. Darger requested quantifying this edit such as number of members and drugs.

ADHD utilization

The Committee reviewed utilization of ADHD drugs for members 21 years and younger. Preuss questioned if certain providers prescriber more than others. Darger commented that utilization is across the board. Darger asked to compare PMPM of ADHD drugs of other Medicaid States and bring proposed criteria to review at the next meeting.

Orkambi PA review

The Committee reviewed PA criteria for Orkambi and utilization of cystic fibrosis drugs. Orkambi is the only cystic fibrosis drug with clinical PA criteria. James Wallace, pediatric pulmonologist from South Dakota provided public comment. Ladwig made the motion to remove clinical PA on Orkambi. Holland seconded the motion. The motion was unanimously approved via roll call vote.

Evrysdi

Jockheck stated Evrysdi would fall under the purview of this Committee unlike other drugs currently available for spinal muscular atrophy (SMA). Jeremy Whalen from Genentech provided public comment on Evrysdi. Van Gilder suggested reviewing proposed PA criteria at the next meeting.

Adjournment

The next meeting is scheduled for March 5, 2021. The June meeting is tentatively scheduled on June 11, 2021. Petrik made a motion to adjourn the meeting and Oehlke seconded the motion. The motion passed unanimously by everyone leaving, and the meeting adjourned at 2:55 PM.